Calcium channel blockade and cardiovascular prognosis in the european trial on isolated systolic hypertension

Hypertension

Volumn 32, Issue 3, 1998, Pages 410-416

  Staessen, Jan A ^a   Thijs, Lutgarde ^b   Fagard, Robert H ^b   Birkenhäger, Willem H ^b   Arabidze, Guramy ^b   Babeanu, Speranta ^b   Gil Extremera, Blas ^b   Bulpitt, Christopher J ^b   Davidson, Christopher ^b   De Leeuw, Peter W ^b   Efstratopoulos, Aris D ^b   Fletcher, Astrid E ^b   Fogari, Roberto ^b   Jääskivi, Matti ^b   Kawecka Jaszcz, Kalina ^b   Nachev, Choudomir ^b   Petrie, James C ^b   Seux, Marie Laure ^b   Tuomilehto, Jaakko ^b   Webster, John ^b   Yodfat, Yair ^b   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

Calcium channel blockers; Hypertension, isolated systolic; Prognosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE; PLACEBO;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EUROPE; HEART FAILURE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTOLIC HYPERTENSION;

EID: 0031681305     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.3.410     Document Type: Article

References (18)

1. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, Bulpitt CJ, De Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764. [Correction. Lancet. 1997;350:1636.]
2. Amery A, Birkenhäger W, Bulpitt CJ, Clement D, De Leeuw P, Dollery CT, Fagard R, Fletcher A, Forette F, Leonetti G, O'Brien ET, O'Malley K, Rodicio JL, Rosenfeld J, Staessen J, Strasser T, Terzoli L, Thijs L, Tuomilehto J, Webster J. Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clin Exp Res. 1991;3:287-302.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-3264.
4. Fletcher A, Spiegelhalter D, Staessen J, Thijs L, Bulpitt C. Implications for trials in progress of publication of positive results. Lancet. 1993;342: 653-657.
5. Staessen J, Fagard R, Amery A. Isolated systolic hypertension in the elderly: implications of SHEP for clinical practice and for the ongoing trials. J Hum Hypertens. 1991;5:469-474.
6. Winker MA, Murphy MB. Isolated systolic hypertension in the elderly. JAMA. 1991;265:3301-3302.
7. Goa KL, Sorkin EM. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of hypertension. Drugs. 1987;33:123-155.
8. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92: 1326-1331.
9. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-625.
10. Furberg CD, Psaty BM. Calcium antagonists: not appropriate as first line antihypertensive agents. Am J Hypertens. 1996;9:122-125.
11. Furberg CD, Psaty BM. JNC VI: timing is everything. Lancet. 1997;350: 1413-1414.
12. Heckbert SR, Longstreth WT Jr, Psaty BM, Murros KE, Smith NL, Newman AB, Williamson JD, Bernick C, Furberg CD. The association of antihypertensive agents with MRI white matter findings and the Modified Mini-Mental State Examination in older adults. J Am Geriatr Soc. 1997; 45:1423-1433.
13. Psaty BM, Furberg CD. Clinical implications of the World Health Organization-International Society of Hypertension statement on calcium antagonists. J Hypertens. 1997;15:1197-1200.
14. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645-652.
15. 41st World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ. 1990;24:606-609.
16. Staessen JA, Thijs L, Bijttebier G, Clement D, O'Brien ET, Palatini P, Rodicio J, Rosenfeld J, Fagard R, on behalf of the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Determining the trough-to-peak ratio in parallel-group trials. Hypertension. 1997;29:659-667.
17. Staessen JA, Fagard R, Thijs L, Celis H, Birkenhäger WH, Bulpitt CJ, De Leeuw PW, Fletcher AE, Babarskiene MR, Forette F, Kocemba J, Laks T, Leonetti G, Nachev C, Petrie JC, Tuomilehto J, Vanhanen H, Webster J, Yodfat Y, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Arch Intern Med. 1998. In press.
18. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris MCAA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond MG. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): a randomized controlled trial. JAMA. 1996;276: 785-791.